P1.100. Impact of Immunotherapy Introduction on Real-World Treatment Patterns for Advanced Esophageal Cancer: A Retrospective Database Cohort Study From Japan
Clicks: 2
ID: 325693
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #22 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background Treatment of advanced esophageal cancer (EC) has evolved with immune checkpoint inhibitors (ICIs), including nivolumab or pembrolizumab plus doublet chemotherapy (IO-chemo) and nivolumab plus ipilimumab as first-line therapy, and nivolumab and pembrolizumab as second-line therapy. Here, we report a temporal shift in real-world treatment patterns for advanced EC in Japan. Methods This observational, retrospective cohort study using a hospital-based administrative claims database (Medical Data Vision Co., Ltd) included patients aged >18 years with EC who had stage IVB disease or metastasis and initiated EC practice guideline-listed 1L therapy from 2017 to 2024. Regimens in each line of therapy were defined as any combination of agents indicated for EC that was prescribed within 14 days of therapy initiation and considered ended when all agents in the regimen were not prescribed for >90 days or a different EC agent was started. Treatment patterns were assessed by year of 1L therapy initiation. Results Of 2,657 pts included, 85% were male and the median age at 1L initiation was 70 years (IQR: 64-75). For 1L therapy, chemotherapy was predominantly used in 2017-2021, while ICI-containing regimens (IO-chemo and nivolumab + ipilimumab) became most common in 2022-2024 (table). For 2L therapy, taxanes were most frequently used in patients initiating 1L therapy in 2017-2019, while nivolumab monotherapy became most common in those initiating 1L therapy in 2020-2021. Following the adoption of 1L ICI regimens in 2022, nivolumab use declined and taxane use increased. Increased use of ICI-containing regimens coincided with longer 1L and 2L treatment durations. Conclusion The introduction of ICIs in clinical practice in Japan has shifted treatment patterns for advanced EC, with a trend toward prolonged treatment durations for both 1L and 2L therapy. Detailed data in post-1L ICI era, including baseline characteristics and treatment durations by 1L regimen type (IO-chemo and nivolumab + ipilimumab), will be presented.
| Reference Key |
openalex_W7203932340
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Shun Yamamoto, Yorifumi Kikko, Bruno Casaes Teixeira, Thomas Benoit Laurent, Shogo Ikeda, Akihiko Inagawa, Daisuke Takahashi, Yuko Matsuda, J Abiram, Hiroshi Saeki |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.248
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.